Resources | NITAG RESOURCE CENTER

2024 ∙ ACIP

ACIP Evidence to Recommendations for Use of Moderna RSV Vaccine (mResvia) in All Adults Aged ≥75 years and in Adults Aged 60–74 at Increased Risk of Severe RSV Disease

2024 ∙ ACIP

GRADE of Protein subunit RSV vaccines (GSK Arexvy and Pfizer Abrysvo) in older adults

2024 ∙ ACIP

GRADE of Moderna mRNA RSV Vaccine (mResvia) in older adults

2024 ∙ NACI

NACI Interpretation Guide – Health Economics

2024 ∙ Eliza Dryer, Shefer, Abigail, Shalini Desai, Lance Rodewald, Magdalena Bastias, Nathalie El Omeiri, Sidy Ndiaye, Kori Cook, Louise Henaff, Erin Kennedy

Development of a maturity assessment tool to evaluate and strengthen National Immunization Technical Advisory Groups (NITAGs)

2024 ∙ STIKO

Resolution on the STIKO recommendation for a standard vaccination against diseases caused by respiratory syncytial viruses (RSV) for persons ≥ 75 years of age and for the indication vaccination of persons aged 60 to 74 years with risk factors

2024 ∙ NACI

Statement on the prevention of respiratory syncytial virus disease in older adults

2024 ∙ ACIP

ACIP Evidence to Recommendations for Use of Protein Subunit RSV vaccines (GSK Arexvy or Pfizer Abrysvo) in All Adults Aged ≥75 years and in Adults Aged 60–74 at Increased Risk of Severe RSV Disease

2024 ∙ ACIP

ACIP Evidence to Recommendations for Use of Moderna RSV Vaccine (mResvia) in All Adults Aged ≥75 years and in Adults Aged 60–74 at Increased Risk of Severe RSV Disease

2024 ∙ NACI

Supplemental guidance from NACI on influenza vaccination in adults 65 years of age and older